These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 34176393)
1. Recent advances and future perspectives in the pharmacological treatment of Giacobbe DR; Magnasco L; Sepulcri C; Mikulska M; Koehler P; Cornely OA; Bassetti M Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1205-1220. PubMed ID: 34176393 [TBL] [Abstract][Full Text] [Related]
2. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris. Kordalewska M; Lee A; Park S; Berrio I; Chowdhary A; Zhao Y; Perlin DS Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632013 [No Abstract] [Full Text] [Related]
3. Invasive Oliva A; De Rosa FG; Mikulska M; Pea F; Sanguinetti M; Tascini C; Venditti M Expert Rev Anti Infect Ther; 2023; 21(9):957-975. PubMed ID: 37494128 [TBL] [Abstract][Full Text] [Related]
4. An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date. Colombo RE; Vazquez JA Expert Opin Pharmacother; 2021 May; 22(7):797-807. PubMed ID: 33599551 [TBL] [Abstract][Full Text] [Related]
6. Review of treatment options for a multidrug-resistant fungus: Candida auris. Wang S; Pan J; Gu L; Wang W; Wei B; Zhang H; Chen J; Wang H Med Mycol; 2024 Jan; 62(1):. PubMed ID: 38066698 [TBL] [Abstract][Full Text] [Related]
7. Rezafungin Helleberg M; Jørgensen KM; Hare RK; Datcu R; Chowdhary A; Arendrup MC Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015032 [TBL] [Abstract][Full Text] [Related]
8. Assessment of the Li J; Coste AT; Bachmann D; Sanglard D; Lamoth F Microbiol Spectr; 2021 Dec; 9(3):e0139521. PubMed ID: 34730380 [TBL] [Abstract][Full Text] [Related]
9. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Hoenigl M; Sprute R; Arastehfar A; Perfect JR; Lass-Flörl C; Bellmann R; Prattes J; Thompson GR; Wiederhold NP; Al Obaidi MM; Willinger B; Arendrup MC; Koehler P; Oliverio M; Egger M; Schwartz IS; Cornely OA; Pappas PG; Krause R Expert Opin Investig Drugs; 2022 Aug; 31(8):795-812. PubMed ID: 35657026 [TBL] [Abstract][Full Text] [Related]
10. Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician. Lamoth F Infect Drug Resist; 2023; 16():1087-1097. PubMed ID: 36855391 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis. Wiederhold NP; Najvar LK; Shaw KJ; Jaramillo R; Patterson H; Olivo M; Catano G; Patterson TF Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427304 [TBL] [Abstract][Full Text] [Related]
12. Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix. August BA; Kale-Pradhan PB Pharmacotherapy; 2024 Jun; 44(6):467-479. PubMed ID: 38721866 [TBL] [Abstract][Full Text] [Related]
13. The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective. Ordaya EE; Clement J; Vergidis P Mycopathologia; 2023 Dec; 188(6):937-948. PubMed ID: 37470902 [TBL] [Abstract][Full Text] [Related]
14. Invasive Candida auris infections in Kuwait hospitals: epidemiology, antifungal treatment and outcome. Khan Z; Ahmad S; Benwan K; Purohit P; Al-Obaid I; Bafna R; Emara M; Mokaddas E; Abdullah AA; Al-Obaid K; Joseph L Infection; 2018 Oct; 46(5):641-650. PubMed ID: 29949089 [TBL] [Abstract][Full Text] [Related]
19. Rezafungin: a novel antifungal for the treatment of invasive candidiasis. Ham YY; Lewis JS; Thompson GR Future Microbiol; 2021 Jan; 16(1):27-36. PubMed ID: 33438477 [TBL] [Abstract][Full Text] [Related]